Published in Infect Immun on May 01, 1988
Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis (1983) 6.15
Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med (1980) 5.32
Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis (1983) 3.19
The epidemiology of pneumococcal disease in infants and children. Rev Infect Dis (1981) 2.76
An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods (1986) 2.50
X-linked immune deficiency (xid) of CBA/N mice. Curr Top Microbiol Immunol (1986) 1.68
Current status of immunological adjuvants. Annu Rev Immunol (1986) 1.65
Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet (1986) 1.42
Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3. Infect Immun (1983) 1.21
Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J Infect Dis (1984) 1.18
The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J Immunol (1981) 1.17
The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J Immunol (1984) 1.08
Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of age. J Pediatr (1987) 1.03
Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity. Int Arch Allergy Appl Immunol (1981) 1.02
Immunogenic properties of octasaccharide-protein conjugates derived from Klebsiella serotype 11 capsular polysaccharide. Infect Immun (1985) 0.93
Maternal immunization and the immune response of neonates to pneumococcal polysaccharides. Rev Infect Dis (1987) 0.92
Immunomodulating properties of two synthetic adjuvants: dependence upon type of antigen, dose, and time of administration. Cell Immunol (1984) 0.91
Serum opsonic activity for Haemophilus influenzae type b in infants immunized with polysaccharide-protein conjugate vaccines. J Infect Dis (1985) 0.89
Adjuvant effects of nonionic block polymer surfactants on liposome-induced humoral immune response. J Immunol (1987) 0.88
The in vitro B-cell response to pneumococcal polysaccharides in adults and neonates. Scand J Immunol (1987) 0.88
Haemophilus influenzae type b polysaccharide-protein conjugate vaccine. Proc Soc Exp Biol Med (1987) 0.88
Measurement of the humoral immune response against Streptococcus pneumoniae type 3 capsular polysaccharide and oligosaccharide containing antigens by ELISA and ELISPOT techniques. J Immunol Methods (1988) 0.86
Immunopotentiating conjugates. Vaccine (1985) 0.81
Immunomodulating peptides. Experientia (1986) 0.79
Immunogenicity of a synthetic glucosyl-alpha(1,3)-glucosyl protein conjugate. J Immunol (1985) 0.78
Capsular polysaccharide vaccines today. Infection (1984) 0.78
Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev (1995) 3.12
Influence of cyclophosphamide on the delayed hypersensitivity of the mouse. Ann Immunol (Paris) (1974) 2.38
Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities. J Virol (1984) 2.17
Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. Antonie Van Leeuwenhoek (1990) 1.97
Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies. Clin Diagn Lab Immunol (1998) 1.93
Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serum. J Immunol Methods (1983) 1.53
Influence of cyclophosphamide on delayed hypersensitivity and acquired cellular resistance to Listeria monocytogenes in the mouse. Immunology (1977) 1.52
Dimethyl diotadecyl ammonium bromide as adjuvant for delayed hypersensitivity in mice. Immunology (1977) 1.51
Characterization of immunogenic properties of haptenated liposomal model membranes in mice. I. Thymus independence of the antigen. Immunology (1979) 1.47
Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein. J Immunol (1997) 1.43
Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis. J Gen Virol (1983) 1.40
Hydroxyurea interferes with antigen-dependent T-cell activation in vitro. Eur J Clin Invest (2000) 1.40
Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice. J Infect Dis (1995) 1.38
Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis (1998) 1.35
Killed Listeria monocytogenes vaccine becomes protective on addition of polyanions. Nature (1977) 1.34
Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect Immun (1997) 1.28
Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG. Infect Immun (1994) 1.28
Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev (1993) 1.26
Transformation of type polysaccharide antigen synthesis and hemolysin synthesis in streptococci. J Bacteriol (1968) 1.22
Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3. Infect Immun (1983) 1.21
Nontoxigenic strains of Clostridium difficile lack the genes for both toxin A and toxin B. J Clin Microbiol (1991) 1.20
The influence of cyclophosphamide on antibody formation in the mouse. Ann Immunol (Paris) (1975) 1.18
Delayed hypersensitivity in the mouse induced by hapten-carrier complexes. Immunology (1975) 1.15
Membrane fusion activity of Semliki Forest virus in a liposomal model system: specific inhibition by Zn2+ ions. Virology (1997) 1.15
Adjuvanticity of lactobacilli. I. Differential effects of viable and killed bacteria. Clin Exp Immunol (1979) 1.15
Loss of type antigen in a type 3 streptococcus and identification of the determinant disaccharide of the remaining antigen. J Gen Microbiol (1967) 1.14
Estimation of classical pathway of mouse complement activity by use of sensitized rabbit erythrocytes. J Immunol Methods (1980) 1.12
Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. J Virol (1985) 1.11
In vitro stimulation of spleen cells of the mouse by DNP--carrier complexes. Immunology (1974) 1.11
Differences in complement activation between complement-resistant and complement-sensitive Moraxella (Branhamella) catarrhalis strains occur at the level of membrane attack complex formation. Infect Immun (1994) 1.10
New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun (2010) 1.10
Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates. Infect Immun (1989) 1.07
Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents (2001) 1.06
Cells involved in the graft-versus-host reaction in vitro. Immunology (1973) 1.06
Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable? Clin Diagn Lab Immunol (2001) 1.05
The role of complement in monoclonal antibody-mediated protection against virulent Semliki Forest virus. Immunology (1986) 1.04
Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates. Infect Immun (1991) 1.04
Specificity of murine delayed-type hypersensitivity to conjugates of large or small haptens on protein carriers bearing lipid groups. Immunology (1978) 1.03
X-linked genetic control of hapten-polysaccharide-mediated specific immune unresponsiveness in CBA/N mice. J Immunol (1978) 1.03
Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity. Int Arch Allergy Appl Immunol (1981) 1.02
Immunochemistry of the carbohydrate antigens of some Streptococcus salivarius strains. J Gen Microbiol (1971) 1.02
Estimation of the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 by inhibition ELISA. Mol Immunol (1989) 1.02
The role of Peyer's patch cells in antibody formation. Immunology (1973) 1.01
DDA as an immunological adjuvant. Res Immunol (1992) 1.01
Preparation of a semisynthetic vaccine to Streptococcus pneumoniae type 3. Infect Immun (1983) 1.01
Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells (PBMC) and enhance HIV-1 replication. Clin Exp Immunol (1997) 1.00
Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants. Infect Immun (1993) 1.00
Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates. Infect Immun (1991) 1.00
Rapid determination of neutralizing antibodies to Semliki Forest virus in serum by enzyme immunoassay in cell culture with virus-specific monoclonal antibodies. J Clin Microbiol (1986) 1.00
Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine. J Gen Virol (1991) 1.00
Comparison of typing methods for Clostridium difficile isolates. J Clin Microbiol (1993) 1.00
Invasive group A streptococcal disease in the Netherlands: evidence for a protective role of anti-exotoxin A antibodies. J Infect Dis (2000) 0.99
Detection of Semliki Forest virus in cell culture by use of an enzyme immunoassay with peroxidase-labeled monoclonal antibodies specific for glycoproteins E1 and E2. J Clin Microbiol (1984) 0.99
Characterization of immunogenic properties of haptenated liposomal model membranes in mice. II. Induction of delayed-type hypersensitivity. Immunology (1981) 0.99
Determination of alternative pathway of complement activity in mouse serum using rabbit erythrocytes. J Immunol Methods (1980) 0.99
CD16 on human gamma delta T lymphocytes: expression, function, and specificity for mouse IgG isotypes. Cell Immunol (1992) 0.98
Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice. Infect Immun (2001) 0.97
Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice. Infect Immun (2001) 0.97
Interactions of killed Listeria monocytogenes with the mouse complement system. Infect Immun (1981) 0.96
New, simple medium for selective recovery of Klebsiella pneumoniae and Klebsiella oxytoca from human feces. J Clin Microbiol (1984) 0.96
Cellular and molecular requirements for X-linked, hapten-specific B-cell blockade in CBA/N mice. J Exp Med (1978) 0.95
Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Vaccine (1993) 0.95
Delayed-type hypersensitivity and acquired cellular resistance in mice immunized with killed Listeria monocytogenes and adjuvants. Immunology (1979) 0.95
Distribution of different cell types in the lymphoid organs of the mouse, as determined with sera against thymus and Peyer's patches. Immunology (1974) 0.94
Fcgamma receptor polymorphisms determine the magnitude of in vitro phagocytosis of Streptococcus pneumoniae mediated by pneumococcal conjugate sera. J Infect Dis (1999) 0.94
Histamine 2 receptor-mediated immunomodulation in the mouse. I. Immunomodulation by the H2 agonist tolazoline. Clin Exp Immunol (1979) 0.94
Guanylate cyclase in Dictyostelium discoideum with the topology of mammalian adenylate cyclase. Biochem J (2001) 0.94
Identification and characterization of DdPDE3, a cGMP-selective phosphodiesterase from Dictyostelium. Biochem J (2001) 0.94
Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines. Vaccine (1994) 0.93
Immunogenic properties of octasaccharide-protein conjugates derived from Klebsiella serotype 11 capsular polysaccharide. Infect Immun (1985) 0.93
Characterization of immunogenic properties of haptenated liposomal model membranes in mice. V. Effect of membrane composition on humoral and cellular immunogenicity. Immunology (1981) 0.93
Effects of variation in time and dose of cyclophosphamide injection on delayed hypersensitivity and antibody formation. Cell Immunol (1977) 0.93
Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine. Clin Diagn Lab Immunol (2001) 0.93
Assessment of complement-mediated killing of Moraxella (Branhamella) catarrhalis isolates by a simple method. Clin Diagn Lab Immunol (1995) 0.92
Cellular and humoral adjuvant activity of mistletoe extract. Immunobiology (1979) 0.92
Killed Listeria monocytogenes vaccine is protective in C3H/HeJ mice without addition of adjuvants. Nature (1980) 0.92
Phage antibodies obtained by competitive selection on complement-resistant Moraxella (Branhamella) catarrhalis recognize the high-molecular-weight outer membrane protein. Infect Immun (1998) 0.92
Measurement of the humoral immune response against Streptococcus pneumoniae type 14-derived antigens by an ELISA and ELISPOT assay based on biotin-avidin technology. J Immunol Methods (1990) 0.92
Immunomodulating properties of two synthetic adjuvants: dependence upon type of antigen, dose, and time of administration. Cell Immunol (1984) 0.91
Cells involved in the in vitro stimulation by DNP-carrier complexes of in vivo primed mouse spleen cells. Immunology (1974) 0.91
Effect of the adjuvant dimethyl dioctadecyl ammonium bromide on the humoral and cellular immune responses to encephalomyocarditis virus. Antiviral Res (1983) 0.90